Nasdaq · Healthcare
Apyx Medical Corp (APYX)
As-reported financials and recent SEC filings for Apyx Medical Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$52.8M
Net income
$-11.2M
Net margin
-21.2%
Diluted EPS
—
ROE
-75.6%
P/E (TTM)
—
Market cap
—
Debt / equity
2.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M |
| Gross profit | $33.0M | $29.4M | $33.8M | $29.1M | $33.6M |
| Operating income | $-6.4M | $-18.8M | $-17.3M | $-23.6M | $-14.4M |
| Net income | $-11.2M | $-23.5M | $-18.7M | $-23.2M | $-15.2M |
| Diluted EPS | — | — | $-0.54 | $-0.67 | $-0.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →DEF 14A2026-06-26
View on EDGAR →42026-06-17
View on EDGAR →8-K2026-06-17
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Largest Healthcare peers
Go deeper on APYX
Search Apyx Medical Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.